Back to News
Market Impact: 0.35
AstraZeneca's Enhertu Gets NICE Recommendation For HER2 Low Metastatic Breast Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
AstraZeneca and Daiichi Sankyo's Enhertu received a positive NICE recommendation for reimbursement in England for eligible patients with HER2-low metastatic disease. The recommendation expands potential patient access to the cancer therapy in England and is a positive commercial and regulatory milestone for both drugmakers.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
AZN0.65
More News
- UN mission finds evidence of U.S. war crimes in Iran; Washington rejects report
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- Waymo to launch robotaxis in Singapore, its first Southeast Asia market, by 2028
- UK Lawmakers Say Thames Creditors Have Been Joyriding Family Car
- Warsh spooks investors, OpenAI's 'concerning' incidents, Boeing's production problems and more in Morning Squawk
- AI coding agents' 0-click RCE flaw could hand attackers keys to the kingdom
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Vendor Landscape for Institutional Investment Teams
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk